PMID- 16084158
OWN - NLM
STAT- MEDLINE
DCOM- 20051128
LR  - 20131121
IS  - 1097-6744 (Electronic)
IS  - 0002-8703 (Linking)
VI  - 150
IP  - 1
DP  - 2005 Jul
TI  - Comparison of losartan and captopril on heart failure-related outcomes and 
      symptoms from the losartan heart failure survival study (ELITE II).
PG  - 123-31
AB  - BACKGROUND: Blockade of the renin-angiotensin system with angiotensin-converting 
      enzyme inhibitors improves outcomes and symptoms in patients with heart failure 
      (HF). We compared effects of losartan to captopril on mortality, morbidity, and 
      functional status for patients in the ELITE II study. METHODS AND RESULTS: A 
      total of 3152 patients, aged 60 years or older, with New York Heart Association 
      (NYHA) classes II to IV HF and ejection fraction < or = 40% were assigned to 
      receive losartan 50 mg once daily or captopril 50 mg 3 times daily. Outcome 
      measures included all-cause and HF-related mortality, hospitalizations, and 
      discontinuations; change in NYHA class; and quality of life (QoL). HF-related 
      outcomes were not significantly different between therapies. Similar improvements 
      from baseline (P < .01) in NYHA class were observed within both treatment groups. 
      Among 1856 QoL participants, 1343 patients survived at least 1 year; the QoL for 
      1-year survivors improved in both treatment groups (P < .001 vs baseline) and did 
      not differ between groups. CONCLUSIONS: In ELITE II, the effects of losartan on 
      HF-related outcomes, NYHA class, and QoL were not superior to those of captopril. 
      Although angiotensin-converting enzyme inhibitors remain the treatment of choice 
      for patients with HF, the similarity of the findings in the present analysis 
      supports a role for angiotensin-receptor antagonists in this patient population.
FAU - Konstam, Marvin A
AU  - Konstam MA
AD  - Division of Cardiology, Tufts-New England Medical Center, Boston, MA 02111, USA. 
      mkonstam@tufts-nemc.org
FAU - Neaton, James D
AU  - Neaton JD
FAU - Poole-Wilson, Philip A
AU  - Poole-Wilson PA
FAU - Pitt, Bertram
AU  - Pitt B
FAU - Segal, Robert
AU  - Segal R
FAU - Sharma, Divakar
AU  - Sharma D
FAU - Dasbach, Erik J
AU  - Dasbach EJ
FAU - Carides, George W
AU  - Carides GW
FAU - Dickstein, Kenneth
AU  - Dickstein K
FAU - Riegger, Gunter
AU  - Riegger G
FAU - Camm, A John
AU  - Camm AJ
FAU - Martinez, Felipe A
AU  - Martinez FA
FAU - Bradstreet, Deborah C
AU  - Bradstreet DC
FAU - Ikeda, Leila S
AU  - Ikeda LS
FAU - Santoro, Emanuela P
AU  - Santoro EP
CN  - ELITE II Investigators
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am Heart J
JT  - American heart journal
JID - 0370465
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 9G64RSX1XD (Captopril)
RN  - JMS50MPO89 (Losartan)
SB  - IM
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Captopril/*therapeutic use
MH  - Female
MH  - Heart Failure/complications/*drug therapy
MH  - Humans
MH  - Losartan/*therapeutic use
MH  - Male
MH  - Survival
EDAT- 2005/08/09 09:00
MHDA- 2005/12/13 09:00
CRDT- 2005/08/09 09:00
PHST- 2004/06/07 00:00 [received]
PHST- 2004/10/26 00:00 [accepted]
PHST- 2005/08/09 09:00 [pubmed]
PHST- 2005/12/13 09:00 [medline]
PHST- 2005/08/09 09:00 [entrez]
AID - S0002-8703(05)00009-8 [pii]
AID - 10.1016/j.ahj.2004.10.035 [doi]
PST - ppublish
SO  - Am Heart J. 2005 Jul;150(1):123-31. doi: 10.1016/j.ahj.2004.10.035.